Sector ratings Genmab A/S

Equities

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 17/09/2024 pm IST			5-day change	1st Jan Change
1,775.00 ^DKK	-0.08%		-4.29%	-17.63%

16/09	Genmab Reports 'Encouraging' Data From Phase 1/2 Study of Investigational Ovarian Cancer Drug	MT
16/09	Genmab Reports 'Encouraging Response Rate' from Investigational Ovarian Cancer Treatment Trial	MT

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Valuation	ESG Refinitiv	Capi. ($)
GENMAB A/S		A-	16.82B
VERTEX PHARMACEUTICALS INCORPORATED		B+	126B
REGENERON PHARMACEUTICALS, INC.		B+	124B
ARGENX SE	-	B	32.29B
BIONTECH SE	-	B+	29.36B
BEIGENE, LTD.	-	B	20.89B
WUXI APPTEC CO., LTD.		A-	16.04B
INSMED INCORPORATED	-	C	12.58B
NEUROCRINE BIOSCIENCES, INC.		C+	12.34B
SAREPTA THERAPEUTICS, INC.		C+	11.86B
ZEALAND PHARMA A/S	-	B	9.68B
LEGEND BIOTECH CORPORATION	-	D	9.39B
ASCENDIS PHARMA A/S	-	C+	8B
HALOZYME THERAPEUTICS, INC.		A-	7.97B
AKESO, INC.	-	B-	7.95B
EXELIXIS, INC.		B	7.84B
Average		B	28.36B
Weighted average by Cap.		B